Ensysce Biosciences, Inc. (ENSC)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.57
- As of
Kresmion compiles this page from ENSC's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Ensysce Biosciences, Inc. (ENSC): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-29.
See the full ENSC dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ENSC on one page. Preview it with sample data, then open it live with a free account.
Preview the ENSC dossierActive signals for ENSC
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 60.8%, EPS $-0.20 vs $-0.51 estimate
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +494% to ENSC (2026Q2)
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 34.4% - EPS $-0.79 vs $-1.2036 estimate
- mediumEARNINGS_MISS
Q3-2025: Missed consensus by 46.2% - EPS $-1.29 vs $-0.8823 estimate
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 41.6% - EPS $-0.75 vs $-1.2852 estimate
FREE, NO ACCOUNT
Every signal on ENSC, as it fires
You are seeing 5 of 6 signals recorded on ENSC since 2026-05-29.
The five above landed across 3 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ENSC (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 293602504 · 2026Q2 | $25K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ENSC
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
ENSC against its peers
ENSC's operating margin of -202.1% ranks in the 72nd percentile of 8 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | ENSC | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 5.1M USD | 1.2M USD | 75 | 9 |
| Operating margin | -202.1% | -635.8% | 72 | 8 |
| Net margin | -200.8% | -698.3% | 61 | 8 |
| Return on equity | -316.6% | -154.3% | 28 | 15 |
| 1 year | -75.3% | -81.6% | 56 | 16 |
Peers (21): IMRN, OTLC, TRAW, BCLI, OSRH, MTVA, LGVN, AZTR, ZEOX, CNSP, CURX, CMMB, SKYE, ADIL, CALC, TOVX, KALA, SNTI, JAGX, AIM, ACXP. Left out: FBLG (no annual filing), MBRX (no annual filing), NRSN (no annual filing), ADAPY (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (ENSC: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ENSC on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ENSC for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.